ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)
Second Xiangya Hospital of Central South University
Second Xiangya Hospital of Central South University
Alliance for Clinical Trials in Oncology
H. Lee Moffitt Cancer Center and Research Institute
Fondazione Ricerca Traslazionale
Washington University School of Medicine
Emory University
Montefiore Medical Center
University of Illinois at Chicago
Tianjin Medical University Cancer Institute and Hospital
Big Ten Cancer Research Consortium
Intergroupe Francophone de Cancerologie Thoracique
Shanghai Junshi Bioscience Co., Ltd.
Mayo Clinic
University of Southern California
Weill Medical College of Cornell University
University Hospital, Limoges
Gustave Roussy, Cancer Campus, Grand Paris
NuCana plc
The First Affiliated Hospital of Xiamen University
Spanish Lung Cancer Group
University of Birmingham
Fox Chase Cancer Center
Spanish Lung Cancer Group
M.D. Anderson Cancer Center
Peking Union Medical College Hospital
Shanghai Pulmonary Hospital, Shanghai, China
Jeroen Bosch Ziekenhuis
Shanghai Junshi Bioscience Co., Ltd.
M.D. Anderson Cancer Center
Shanghai Chest Hospital
University of Texas Southwestern Medical Center
M.D. Anderson Cancer Center
Assistance Publique Hopitaux De Marseille
Shanghai Jiao Tong University School of Medicine
University of Texas Southwestern Medical Center
Spanish Lung Cancer Group
Hunan Province Tumor Hospital
The First Affiliated Hospital of Xinxiang Medical College
Intergroupe Francophone de Cancerologie Thoracique
University of Michigan Rogel Cancer Center
The First Affiliated Hospital of Guangzhou Medical University
Barbara Ann Karmanos Cancer Institute
Rennes University Hospital
Intergroupe Francophone de Cancerologie Thoracique
Case Comprehensive Cancer Center
Hoosier Cancer Research Network
Spanish Lung Cancer Group
Swiss Cancer Institute
SCRI Development Innovations, LLC
Hunan Province Tumor Hospital